In neuroendocrine tumor cell lines, different MEK inhibitors have been reported to demonstrate antitumoral effects in vitro [34,35,36,37], as has been reported for PD0325901 [35], U0126 [36], and trametinib [37]. This evidence concerns the gene MAP2K7 and neuroendocrine neoplasm.